Jefferies raised the firm’s price target on Omega Healthcare (OHI) to $45 from $43 and keeps a Hold rating on the shares as part of a broader research note previewing 2026 for Healthcare REITs. The firm expects another challenging year for lab landlords as elevated market vacancy and a 9.6% decline in trailing-12-month biotech funding will drive below-average retention in 2026, the analyst tells investors in a research note. For Omega, Jefferies warns that the REIT has a high bar for acquisition volume that it may have trouble clearing while also trading at a reasonable valuation.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on OHI:
- Omega Healthcare price target raised to $46 from $44 at Truist
- Omega Healthcare price target raised to $48 from $45 at Wells Fargo
- Omega, Alphabet, Honeywell, Freeport, DoorDash: Trending by Analysts
- Omega Healthcare initiated with a Buy at UBS
- Omega Healthcare: Strong Buy Rating Driven by Strategic Investments and Positive Market Trends